CHRS: Don’t Miss Coherus at J.P. Morgan Healthcare!

Company Overview

Coherus BioSciences (NASDAQ: CHRS) – now branding itself as Coherus Oncology – is a biotech firm in the midst of a strategic transformation. Historically known for its biosimilar drugs (like UDENYCA®, a Neulasta biosimilar for neutropenia), Coherus has pivoted to focus on innovative immuno-oncology therapies (^[1]) (^[1]). In late 2023, the company achieved FDA approval for its novel anti-PD-1 antibody toripalimab (brand name LOQTORZI®), marking the first U.S.-approved PD-1 inhibitor developed in China. Coherus is positioning LOQTORZI for niches such as nasopharyngeal carcinoma while pursuing broader cancer indications. This transition comes as Coherus prepares to present at the J.P. Morgan Healthcare Conference, a venue where management will showcase its pipeline – which now includes next-generation immunotherapies acquired via the 2023 takeover of Surface Oncology (adding candidates like CHS-114, an anti-CCR8 antibody, and an IL-27 inhibitor) (^[2]) (^[3]). In short, Coherus has evolved from a biosimilar player into a development-stage oncology company, using recent asset sales to bankroll its R&D ambitions.

Dividend Policy and Shareholder Returns

Coherus does not pay any dividend, and it has never paid one in its history (^[4]). Management has explicitly stated that it has no plans to initiate cash dividends in the foreseeable future, opting instead to reinvest any earnings into product development and growth (^[4]) (^[4]). Consequently, the stock’s dividend yield is 0%, and shareholder returns depend entirely on stock price appreciation (or depreciation). In fact, Coherus’s share price has faced heavy pressure over the past year – recently trading almost 69% below its 52-week high (^[5]). This decline reflects both the market’s skepticism and the company’s strategic shift (as Coherus shed revenue-generating assets in exchange for cash). The board also confirmed it does not intend to distribute proceeds from asset sales as any special dividend (^[4]), signaling that available capital will be used to fortify the balance sheet and fund the pipeline rather than returned to shareholders. For investors, this means Coherus is a pure capital-gains story, with no income component for now.

Balance Sheet: Leverage and Debt Maturities

Coherus had substantial debt, but it is aggressively deleveraging using asset sale proceeds. As of year-end 2023, the company carried $230 million of 1.5% Convertible Senior Notes due April 2026 (^[6]). These notes were issued in 2020 (conversion price ~$19.26, far above the current stock price) and represented a looming maturity that far exceeded Coherus’s earnings capacity. In addition, Coherus had a term loan facility: in May 2024 it entered into a $38.7 million senior secured term loan due 2029, which accrues interest at 8% plus SOFR (~12% effective) and is interest-only until maturity (^[4]) (^[4]). This 2029 term loan was used to refinance prior higher-cost debt – specifically to fully retire “2027 Term Loans” that had an outstanding principal of $250 million at the start of 2024 (^[6]) (^[6]). Notably, Coherus also raised $37.5 million in May 2024 through a Revenue Purchase and Sale Agreement, effectively borrowing against future UDENYCA sales in exchange for a royalty obligation (^[4]).

By late 2024, the balance sheet still reflected high leverage (convertible notes, the new term loan, and the royalty liability). However, Coherus announced a transformative deal in December 2024: the divestiture of its UDENYCA franchise for up to $558.4 million (^[1]) (^[1]). This deal (closed in Q2 2025) was expressly designed to wipe out Coherus’s major debts. Management indicated it would allocate part of the UDENYCA sale proceeds to fully repay the $230.0 million 2026 convertible notes and to buy out the remaining royalty obligation for $47.7 million tied to the revenue interest financing (^[4]) (^[4]). In fact, immediately upon closing the sale in April 2025, Coherus received $483.4 million in cash upfront from the buyer (^[7]). It used these funds to eliminate the entire convertible debt and the UDENYCA royalty stream. The smaller 2029 term loan (with ~$38.7M principal) remains in place, but given its relatively modest size and lack of amortization, it is far more manageable (^[4]). The term loan does carry prepayment penalties in its first few years (^[4]), so Coherus has kept it for now. Bottom line: Coherus has dramatically reduced its leverage – going from roughly $500 million in debt obligations in 2023 to only about $38 million of term debt by mid-2025, after applying asset sale proceeds. The onerous $230M convertible due 2026 is no longer a threat, and no significant maturities loom in the next few years.

Liquidity and Coverage

Following these moves, Coherus’s liquidity position is much stronger. The company projected a post-divestiture cash balance of around $250 million after debt paydowns, providing a cash “runway” extending over two years (into 2027) (^[8]). In other words, management believes it has sufficient cash to fund operations and clinical development through key 2025–2026 milestones without needing near-term external capital. This marks a significant turnaround from prior years – Coherus had been burning cash and carrying a shareholder deficit of $(132) million at end-2023 (^[1]).

October 16 — The Switch Flips

Time is ticking to position for Dollar 2.0. Will you be ready?

—

Days

—

Hours

—

Mins

Reserve My Spot — Free Report

Despite the improved cash cushion, Coherus’s coverage ratios remain a concern because the company’s operations are not yet self-funding. Before the transformation, interest expense was high relative to earnings; the firm had net losses and therefore negative interest coverage (no EBIT to cover interest). For context, interest expense in 2023 was $40.5 million, reflecting the burden of the now-retired debt (^[1]). However, interest expense dropped to $27.2 million in 2024 (and was just $5.3 million in Q4’24, versus $10.6 million in Q4’23) (^[1]). This steep decline was “primarily due to fully paying off the $250.0 million of…Term Loans” during 2024 (^[1]). Going forward, with only the 2029 term loan outstanding, annual interest expense should run roughly ~$5 million (8%+SOFR on ~$38M) – a trivial amount relative to the new cash balance. In effect, Coherus has bought itself breathing room: it has the cash to cover R&D and debt service for the next couple of years. However, the core business is still generating operating losses, so the company will be using that cash hoard to “cover” ongoing expenses. Investors should watch how quickly Coherus burns through its $250M war chest. The coverage of fixed obligations by internal cash flow remains weak, but thanks to the divestitures, all critical obligations (debt principal and royalty payments) are covered by the transaction proceeds rather than by earnings. The company also eliminated restrictive covenants (like minimum net sales requirements under its old loans) by paying down debt (^[6]) (^[6]), reducing the risk of technical default. In sum, Coherus now has ample liquidity relative to its near-term needs, but ultimately the cash will need to be deployed efficiently to fund development until (or unless) the company achieves positive cash flow.

Valuation

With Coherus completing its transition to an early-stage oncology company, traditional valuation metrics based on earnings are not very useful – the firm has reported net losses under GAAP and will continue to do so until new products gain traction. There is no P/E ratio to speak of (earnings are negative) and no dividend yield. Instead, investors value Coherus on metrics like revenue, book value, and pipeline potential. In 2024, Coherus’s net revenue was $267.0 million (^[1]), up ~4% despite divestitures (this includes sales from UDENYCA, CIMERLI®, and YUSIMRY® before they were sold, plus initial LOQTORZI sales). However, going forward the company’s revenue will drop dramatically – by 2025, essentially all legacy biosimilar revenue is gone, and the only product sales will come from LOQTORZI (which is still in the early launch phase). Thus, trailing price-to-sales ratios are not very meaningful, as Coherus is effectively a “restart” with a new product lineup.

One way to frame Coherus’s valuation is by its enterprise value relative to cash and pipeline. After the UDENYCA sale, Coherus has about $250M in cash versus a market capitalization in the ballpark of $100–150M at recent share prices (the stock fell under $1 in mid-2025) (^[5]). This suggests an enterprise value near or even below $0 – in other words, the market is valuing Coherus’s business at less than the cash on its balance sheet. Shares outstanding were roughly 116 million as of early 2025 (^[4]) (^[4]), so at a $1 share price the equity value is ~$116M. With $250M cash in hand, the EV is negative once debt is accounted for – a striking situation indicating that investors assign little or no value (even negative value) to Coherus’s drug pipeline. This could imply a few things: either the stock is deeply undervalued relative to asset value, or the market expects the company to burn through its cash with little to show (destroying value). It’s common for development-stage biotechs to trade at a discount when sentiment is poor, and Coherus’s case reflects significant investor skepticism. On an EV/revenue basis, the company looks extremely cheap based on 2024 sales, at well under 1× – but of course those revenues came largely from now-divested assets. A more appropriate valuation approach is a sum-of-parts or DCF of the pipeline, assigning value to LOQTORZI’s commercial prospects and the early-stage candidates. By that measure, Coherus’s current valuation is arguably low if one believes in its drug portfolio (for example, LOQTORZI could generate meaningful revenue in a niche market, and any success in pipeline trials could unlock upside). On the other hand, if LOQTORZI struggles and the pipeline disappoints, the cash will dwindle and even the present low valuation may not be justified. Comparable companies in the small-cap immuno-oncology space (with one approved product and pipeline assets) also often trade at modest valuations, reflecting high risk – Coherus is no exception. Until the company can show revenue growth from LOQTORZI or clinical progress that boosts confidence, its stock is likely to remain in the “penalty box” trading at a discount to its net assets.

Risks and Red Flags

Coherus faces numerous risks that investors should weigh:

The Coming Tech Meltdown — Are You Ready?

Harry Dent + Adam O'Dell reveal the exact small-cap plays that could 10x while big tech tumbles.

HIMX AI partner • Patents • 6.7B users

Claim 75% OFF — $49

– Competitive and Market Risk – PD-1 Landscape: LOQTORZI (toripalimab) enters a crowded immunotherapy market dominated by entrenched giants. Merck’s Keytruda and Bristol Myers’ Opdivo are blockbuster PD-1 inhibitors that command physician loyalty and preferred insurance coverage. Coherus’s toripalimab is approved only for a rare indication (nasopharyngeal cancer) and will need to compete for broader labels. Even if effective, it may need significant price discounting or niche positioning to gain market share against far larger competitors. This could pressure margins and limit sales. Moreover, any delay in securing additional FDA approvals for LOQTORZI in new tumor types would prolong its revenue ramp-up. Commercial execution risk is high, as Coherus must build out oncology marketing capabilities and convince U.S. oncologists to try a lesser-known drug. Early uptake will be closely watched in 2024–2025 to gauge whether Coherus can penetrate the market.

– Pipeline Development Risk: The rest of Coherus’s pipeline consists of early-stage immuno-oncology candidates (such as CHS-114 anti-CCR8 and an IL-27 antibody) that are unproven in the clinic (^[2]). The company is betting that combinations of these agents with toripalimab can yield better cancer outcomes, but this is still highly speculative. Clinical trials may fail to show sufficient efficacy or safety, which would derail the pipeline’s value. Coherus has already experienced a pipeline setback – for example, it scrapped its TIGIT inhibitor program (licensed from Junshi) in early 2024 after initial data disappointed, essentially writing off a $35 million investment (^[9]) (^[9]). This underscores the high attrition rate in drug R&D. Any similar failures with current programs would hurt Coherus’s prospects. The company’s future hinges on a few pipeline shots on goal, so the concentration of risk is high. If none of its oncology assets pan out, Coherus will have spent its cash for naught.

Bryce Paul's #1 Crypto To Buy — October 2025

Insider pick. Early access. Big potential. Instant download.

Only $3
Get Instant Access

– Financial and Dilution Risk: Despite the recent cash infusion, Coherus continues to operate at a loss, and development expenses for multiple clinical programs are significant. The company expects its $250 million cash to fund operations into 2027 (^[8]), but this assumes it can manage spending and perhaps achieve some LOQTORZI revenue. If trials run over-budget or timelines slip, Coherus might need additional funding earlier than anticipated. Equity dilution is a perennial risk – the company has used at-the-market stock offerings in the past (^[7]) and issued shares to Junshi and to acquire Surface Oncology (^[10]) (^[4]). New equity or convertible debt financing could significantly dilute existing shareholders, especially if the stock price remains depressed. Additionally, Coherus may owe milestone or royalty payments to partners (for example, Junshi Biosciences is likely entitled to milestones and royalties on toripalimab sales), which will consume cash as LOQTORZI progresses. All these factors could pressure the financial runway. The market’s current pricing of Coherus below cash value implies an expectation that a large portion of the cash will be burned – a pessimistic view that management will need to overcome.

– Execution and Strategic Risk: Coherus’s rapid strategic pivot – selling off three biosimilar franchises (CIMERLI, YUSIMRY, and now UDENYCA) (^[1]) (^[1]) – leaves the company fully dependent on its oncology strategy. This all-in bet on immuno-oncology is bold but comes with execution challenges. Management must integrate the Surface Oncology assets and manage a 30% reduction in headcount post-divestitures (^[1]), all while advancing multiple trials. There could be operational hiccups in scaling down the biosimilar business and ramping up the oncology efforts. Furthermore, Coherus’s partnership with Junshi Biosciences (toripalimab’s originator) entails some reliance on a Chinese manufacturer and partner. Geopolitical or regulatory complications (e.g. FDA inspection issues, trade restrictions) could pose a supply chain risk for the drug. Any delay in delivering on milestones – be it trial readouts or commercialization targets – could weaken investor confidence further. Lastly, the company’s decision not to share any sale proceeds with investors (no buybacks or dividends) means management is asking shareholders for patience and trust that investing all capital in R&D will pay off. If the strategy falters, shareholders have little recourse and no immediate cash returns, which is a governance consideration.

In summary, Coherus exhibits red flags typical of small biotech turnarounds: heavy historical losses, dependence on one new product, and a need to execute flawlessly in a high-risk arena. The stock’s severe decline and negative enterprise value reflect these concerns. Investors should monitor how Coherus handles these risks in the coming quarters.

Open Questions

Given Coherus’s situation, several key questions remain open for investors and analysts attending the J.P. Morgan Healthcare Conference:

– Can Coherus’s flagship PD-1 drug LOQTORZI gain meaningful traction? Early sales in nasopharyngeal carcinoma will be a proving ground – and will Coherus be able to expand LOQTORZI’s label (e.g., into lung cancer or other common tumors) to drive revenue growth? The company needs to demonstrate that it can compete with, or complement, entrenched immunotherapies in practice. Results from ongoing combination trials and any plans for new indications will be crucial.

– Will Coherus’s oncology pipeline justify the cash investment? Investors will be looking for clinical readouts in 2025–2026 from Coherus’s pipeline (e.g. CHS-114 anti-CCR8 trials) that could validate its scientific approach (^[7]). Positive data could attract partners or investors, while lackluster results might leave Coherus with a cash burn and no breakthrough to show. Can Coherus secure partnerships or non-dilutive funding (e.g. out-licensing certain rights) to share development costs and enhance credibility?

– How will the large cash reserve be utilized, and is it truly sufficient? With ~$250 million in post-sale cash, Coherus claims to be funded for two+ years (^[8]). But is this assuming best-case spending or minimal revenue? If LOQTORZI sales underperform or trials become more expensive, the cash runway could shorten. Conversely, might Coherus choose to deploy some cash strategically – for instance, making targeted acquisitions or in-licensing synergistic assets to bolster its pipeline? Management’s capital allocation strategy (beyond just funding internal R&D) remains to be seen.

– What is the endgame for Coherus’s transformation? Now that the legacy biosimilar business is essentially gone, Coherus is a development-stage oncology company with one marketed product. Will the company attempt to rebuild a commercial portfolio and become a profitable standalone oncology firm by 2027? Or is the likely goal to prove the pipeline’s worth and then seek a partnership or acquisition by a larger pharma? The outcome of ongoing trials and the interest they garner from big pharma could hint at Coherus’s longer-term path. Additionally, investors may ask if Coherus would consider re-entering the biosimilar arena or other revenue streams if the oncology plan takes longer than expected – or is the commitment to oncology now absolute?

As Coherus presents at the J.P. Morgan conference, these questions will be top of mind. The company’s investment thesis has shifted: it’s no longer about steady biosimilar cash flows (those are gone), but about high-risk/high-reward oncology development. Success is far from guaranteed, but with debt largely cleaned up and cash in the bank, Coherus has given itself a fighting chance. The next 18–24 months – with pivotal trial results and initial LOQTORZI commercialization – will likely determine whether this bold transformation can deliver value or whether further challenges await. Investors should closely follow Coherus’s updates at the conference and beyond, as the story is still unfolding.

Sources: Coherus BioSciences SEC filings (^[4]) (^[4]); Coherus Investor Relations presentations and press releases (^[8]) (^[1]); Biospace and GlobeNewswire news releases (^[1]) (^[1]); and other first-party company disclosures and financial reports.

Sources

For informational purposes only; not investment advice.